Giá CelsiusCEL

Announcement on Resumption of CEL-ERC20 Network Withdrawal Services | Bitget Support Center https://www.bitget.com/support/articles/12560603822106?appVersion=2.50.6&time=1738620424258&androidSdk=30&language=en_US&appTheme=dark

delist ?

0.6 soon buy buy😍

Biotechnology stocks are among the most high-risk, high-reward stocks in the market. Many biotech companies are working to develop one or or even a handful of world-changing drugs to address billion-dollar markets. The fates of these often volatile stocks are tied closely to study data and approval decisions from the U.S. Food and Drug Administration or other drug regulators.The biotech group struggled as a whole in 2024, but analysts say the innovation that has always supported the biotech industry is alive and well. Here are seven top biotech stocks with "buy" or "hold" ratings from Argus analystsVertex Pharmaceuticals specializes in developing therapies to treat cystic fibrosis, or CF. Vertex also owns the rights to 60% of the profits from sales of CRISPR Therapeutics AG's (CRSP) gene-editing therapy exa-cel, which was approved by the FDA for treating sickle cell disease in December 2023 and for treating transfusion-dependent beta thalassemia just six weeks later. Analyst Jasper Hellweg says he is bullish on Vertex's growth outlook thanks to its market-leading CF portfolio, its successful diversification outside of CF and its healthy balance sheet. Argus has a "buy" rating and $550 price target for VRTX stock, which closed at $408.32 on Jan. 7.

Biotechnology stocks are among the most high-risk, high-reward stocks in the market. Many biotech companies are working to develop one or or even a handful of world-changing drugs to address billion-dollar markets. The fates of these often volatile stocks are tied closely to study data and approval decisions from the U.S. Food and Drug Administration or other drug regulators.The biotech group struggled as a whole in 2024, but analysts say the innovation that has always supported the biotech industry is alive and well. Here are seven top biotech stocks with "buy" or "hold" ratings from Argus analystsVertex Pharmaceuticals specializes in developing therapies to treat cystic fibrosis, or CF. Vertex also owns the rights to 60% of the profits from sales of CRISPR Therapeutics AG's (CRSP) gene-editing therapy exa-cel, which was approved by the FDA for treating sickle cell disease in December 2023 and for treating transfusion-dependent beta thalassemia just six weeks later. Analyst Jasper Hellweg says he is bullish on Vertex's growth outlook thanks to its market-leading CF portfolio, its successful diversification outside of CF and its healthy balance sheet. Argus has a "buy" rating and $550 price target for VRTX stock, which closed at $408.32 on Jan. 7.